The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
11C-metomidate PET imaging of adrenocortical cancer
Abstract
The diagnostic potential of positron emission tomography (PET) with carbon-11 metomidate in patients with adrenocortical cancer (ACC) was evaluated. Thirteen PET examinations were performed in 11 patients with CT-detected primary tumours or recurrence and/or metastases from a previously histopathologically proven ACC. The findings at PET were compared with those at CT and verified by histopathology. Six studies (group A) were performed in patients who at the time of imaging were free of medication that could interfere with 11beta-hydroxylase activity and thereby tracer uptake at PET, such as adrenal steroid inhibitors or chemotherapy. The remaining seven studies (group B) were carried out in patients who were monitored during treatment with one or a combination of these drugs. PET visualised all viable tumours with high tracer uptake, and revealed two more lesions than were seen on CT. Three necrotic tumours were detected as false negative observations, as confirmed at surgery and histopathological examination. A true negative observation was obtained at PET in the case of a suspected liver metastasis on CT that was found to have fat vacuolation at histopathological examination of an ultrasonically guided core biopsy specimen. Group A showed apparently higher uptake in normal tissues than group B (adrenal, P=0.03; liver, P=0.01). The metomidate uptake was increased in tumour lesions as compared with normal tissues (adrenal, P=0.02; liver, P=0.005). ACC could be clearly visualised with (11)C-metomidate PET except when the tumour was necrotic. Medication with adrenal steroid inhibitors and chemotherapy decreased the tracer uptake.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It cannot, however, distinguish benign from malignant adrenocortical lesions.”
From Adrenocortical carcinoma (2014) · cites this paper as [113]
In the citing paper
“[11C]MTO PET can distinguish tumors of adrenocortical origin from noncortical lesions (113).”
From Adrenocortical carcinoma (2014) · cites this paper as [113]
Citations
Cites
Incidentally Discovered Adrenal Masses*
Kloos, R. T., Gross, M. D., Francis, I. R., KOROBKIN, M. T., & Shapiro, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-4-460 · Cited by 869
Incidentally discovered adrenal tumors: an institutional perspective.
Mf, H., Cs, G., van Heerden, J. A., Sheedy, P. F., & Dm, I. (1991) · PubMed · Cited by 356
Incidentally DiscoveredAdrenal Mass
Young, W. F., & Bancos, I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-79285-1.00101-1 · Cited by 304
Boland, G. W., Goldberg, M. A., Lee, M. J., Mayo-Smith, W. W., Dixon, J., McNicholas, M. M. J., & Müeller, P. R. (1995) · Radiology · doi:10.1148/radiology.194.1.7997539 · Cited by 222
Performance Characteristics of an Eight-Ring Whole Body PET Scanner
Kops, E. R., Herzog, H. R., Schmid, A., Holte, S., & Feinendegen, L. E. (1990) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199005000-00022 · Cited by 194
Scintigraphic evaluation of clinically silent adrenal masses.
Gross, M. D., Shapiro, B., Francis, I. R., Glazer, G. M., Bree, R. L., Arcomano, M. A., SCHTEINGART, D. E., McLeod, M. K., Sanfield, J. A., & Thompson, N. W. (1994) · PubMed · Cited by 121
PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate.
Bergström, M., Juhlin, C., Bonasera, T. A., Sundín, A., Rastad, J., Åkerström, G., & Långström, B. (2000) · PubMed · Cited by 111
Self-citationFDG-PET in Adrenocortical Carcinoma
Becherer, A., Vierhapper, H., Pötzi, C., Karanikas, G., Kurtaran, A., Schmaljohann, J., Staudenherz, A., Dudczak, R., & Kletter, K. (2001) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497801753131363 · Cited by 102
Bergström, M., Bonasera, T. A., Lu, L., Bergström, E., Backlin, C., Juhlin, C., & Långström, B. (1998) · PubMed · Cited by 95
Self-citationINCIDENTAL ASYMPTOMATIC ADRENAL MASSES DETECTED BY COMPUTED TOMOGRAPHIC SCANNING
Prinz, R. A., Brooks, M. H., Churchill, R., Graner, J. L., Lawrence, A. M., Paloyan, E., & Sparagana, M. (1983) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-198308000-00048 · Cited by 78
Cited by
Sorted by citations
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
The clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781
Adrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Adrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396
Clinical management of adrenocortical carcinoma
Fassnacht, M., & Allolio, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.008 · Cited by 349
Metadata
- Authors
- Khan, T. S., Sundin, A., Juhlin, C., Långström, B., Bergström, M., & Eriksson, B.
- Affiliations
- Uppsala University Hospital (SE)
- Uppsala University (SE)
- Corresponding author
- Eriksson, Barbro
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2003-03
- Volume
- 30
- Issue
- 3
- Pages
- 403-410
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2008345499
- Cited by
- 107
- References
- 17
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 2 · 2022: 5 · 2021: 7 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 6 · 2014: 3 · 2013: 7 · 2012: 7
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- adrenocortical carcinoma, positron emission tomography, tumor necrosis, liver metastasis, cancer detection
- MeSH terms
- Adrenal Cortex Neoplasms, Adult, Aged, Antineoplastic Agents, Carbon Radioisotopes, Etomidate, Female, Humans, Male, Metabolic Clearance Rate, Middle Aged, Organ Specificity, Sensitivity and Specificity, Tissue Distribution, Tomography, Emission-Computed, Reproducibility of Results, Radiopharmaceuticals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
